Clinical Trial Update: Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating adalimumab for cutaneous sarcoidosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoidosis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Wake Forest University | Conditions: Sarcoidosis | Phase 2 | Status: WITHDRAWN